Page 8 - Patient Support Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

May 18, 2021 Manage the Patient Support Program (PSP) for Copaxone Support (Helpline and email address) for new and existing patients, Solus V2 Helpline, assist upon request with other patient support programs or projects to be allocated as and when required by line manager. Start new patients on Copaxone Ensure that new patients understand the product and injection techniques in order to solve their queries with regards to the same Plan quarterly calls / visits to existing Copaxone patients in order to monitor the performance Contact / visit neurologists at least twice a year to provide fe...

Operator Good day and welcome to the alboreto pharma first quarter 2021 earnings conference call. [Operator Instructions] At this time, I would like to turn the conference over to Mr. Paul. Please go ahead, sir. Paul S. Bavier -- Interim President, General Counsel And Secretary Thank you, operator and good morning everyone. Thank you for joining today's call. This morning, Alberto issued a press release highlighting its recent business accomplishments and reporting its financial results for the first quarter ended March 31 2021. This press release is accessible via the company's website at w...

Published: Apr 23, 2021   First and only CD19-targeted antibody drug conjugate (ADC) as a single-agent treatment for adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) ZYNLONTA addresses an unmet need across a broad population of third-line (3L)+ r/r patients, including patients with DLBCL not otherwise specified, DLBCL arising from low grade lymphoma and high-grade B-cell lymphoma ZYNLONTA demonstrated 48.3% overall response rate, 24.1% complete response rate and durable responses in heavily pretreated patients in pivotal LOTIS-2 trial Investor confe...

(0) First and only CD19-targeted antibody drug conjugate (ADC) as a single-agent treatment for adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) ZYNLONTA addresses an unmet need across a broad population of third-line (3L)+ r/r patients, including patients with DLBCL not otherwise specified, DLBCL arising from low grade lymphoma and high-grade B-cell lymphoma ZYNLONTA demonstrated 48.3% overall response rate, 24.1% complete response rate and durable responses in heavily pretreated patients in pivotal LOTIS-2 trial Investor conference call and webcast to b...

Published: Apr 08, 2021 Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults AJOVY® now offers patients greater flexibility with two dosing options available in both an autoinjector and a prefilled syringe AJOVY® is the first and only subcutaneous anti-CGRP treatment with both quarterly (every three months) and monthly dosing options using either the autoinjector or prefilled syringe for the preventive treatment of migraine in adults. AJOVY® is supported by the AJOVY® Teva Support Solutions® (AJOVY® TSS) Patient Support Program, whose...